| Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. (NCT06694025) | Sanofi | 2026-10-01 |
| Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe (NCT07282795) | Sanofi | 2026-10-01 |
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease (NCT07771439) | Sanofi | 2026-09-07 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China (NCT07710872) | Sanofi | 2026-08-20 |
| A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) (NCT07135973) | Sanofi | 2026-08-10 |
| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants (NCT07726914) | Sanofi | 2026-08-06 |
| The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry (NCT07612878) | Sanofi | 2026-07-31 |
| A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease (NCT07688213) | Sanofi | 2026-07-28 |
| Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older (NCT07734649) | Sanofi | 2026-07-22 |
| A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer (NCT07692204) | Sanofi | 2026-07-01 |
| Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea (NCT07621653) | Sanofi | 2026-07-01 |
| An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia (NCT07634692) | Sanofi | 2026-06-15 |
| Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants (NCT07646548) | Sanofi | 2026-06-11 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis (NCT07547436) | Sanofi | 2026-06-08 |
| SAR447971 First-in-human Study (NCT07629336) | Sanofi | 2026-05-26 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) (NCT07222189) | Sanofi | 2026-05-19 |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica (NCT07286214) | Sanofi | 2026-05-12 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (NCT07484230) | Sanofi | 2026-05-08 |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age (NCT07516418) | Sanofi | 2026-04-15 |
| A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice (NCT07556159) | Sanofi | 2026-04-01 |
| Long-Term Outcomes of Teplizumab in Routine Clinical Care (NCT07360080) | Sanofi | 2026-03-19 |
| A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria (NCT07316114) | Sanofi | 2026-03-18 |
| Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) (NCT07457580) | Sanofi | 2026-03-16 |
| An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (NCT07424144) | Sanofi | 2026-03-12 |
| The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis (NCT07467564) | Sanofi | 2026-02-24 |
| Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes (NCT07380711) | Sanofi | 2026-01-28 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease (NCT07184944) | Sanofi | 2026-01-22 |
| Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (NCT07348692) | Sanofi | 2026-01-20 |
| Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (NCT07247188) | Sanofi | 2026-01-20 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis (NCT07185009) | Sanofi | 2026-01-16 |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis (NCT07325292) | Sanofi | 2026-01-14 |
| A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07225569) | Sanofi | 2025-12-29 |
| A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (NCT07285460) | Sanofi | 2025-12-18 |
| Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) (NCT07038473) | Sanofi | 2025-12-17 |
| A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants. (NCT07272629) | Sanofi | 2025-12-04 |
| This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment (NCT07290803) | Sanofi | 2025-11-17 |
| Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa (NCT07170917) | Sanofi | 2025-11-06 |
| A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States (NCT07260110) | Sanofi | 2025-10-31 |
| Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment (NCT07007962) | Sanofi | 2025-10-24 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan (NCT07216079) | Sanofi | 2025-10-15 |
| A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission (NCT07156175) | Sanofi | 2025-10-14 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis (NCT07184996) | Sanofi | 2025-10-08 |
| A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea (NCT07200206) | Sanofi | 2025-10-02 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease (NCT07184931) | Sanofi | 2025-10-01 |
| A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease (NCT07190196) | Sanofi | 2025-09-26 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (NCT07135986) | Sanofi | 2025-09-26 |
| Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy (NCT06941870) | Sanofi | 2025-09-23 |
| A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. (NCT07053423) | Sanofi | 2025-09-22 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype (NCT07190222) | Sanofi | 2025-09-17 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype (NCT07190209) | Sanofi | 2025-09-16 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease (NCT06984627) | Sanofi | 2025-09-02 |
| A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants (NCT07146750) | Sanofi | 2025-08-25 |
| A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia (NCT07086976) | Sanofi | 2025-08-18 |
| The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease (NCT06975865) | Sanofi | 2025-08-12 |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (NCT07088068) | Sanofi | 2025-08-06 |
| Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India (NCT07109297) | Sanofi | 2025-07-31 |
| Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes (NCT06791291) | Sanofi | 2025-07-25 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (NCT06844214) | Sanofi | 2025-07-23 |
| Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events (NCT07734753) | Sanofi | 2025-07-15 |
| Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age (NCT07071558) | Sanofi | 2025-07-14 |
| A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (NCT07103148) | Sanofi | 2025-07-11 |
| A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis (NCT06975722) | Sanofi | 2025-07-07 |
| Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions (NCT07052396) | Sanofi | 2025-07-01 |
| Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (NCT05720455) | Sanofi | 2025-06-15 |
| A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease (NCT06958536) | Sanofi | 2025-06-03 |
| Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults (NCT07002060) | Sanofi | 2025-05-22 |
| Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (NCT06975878) | Sanofi | 2025-05-22 |
| A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia (NCT06714461) | Sanofi | 2025-05-05 |
| A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia (NCT06714448) | Sanofi | 2025-04-29 |
| Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (NCT06907511) | Sanofi | 2025-04-17 |
| Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP) (NCT06968975) | Sanofi | 2025-04-11 |
| Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP (NCT06859099) | Sanofi | 2025-04-01 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis (NCT06867094) | Sanofi | 2025-03-28 |
| A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases (NCT06647069) | Sanofi | 2025-03-27 |
| Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years (NCT06891417) | Sanofi | 2025-03-27 |
| A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (NCT06850051) | Sanofi | 2025-03-19 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06356571) | Sanofi | 2025-03-17 |
| Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany (NCT07002047) | Sanofi | 2025-03-13 |
| Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (NCT06812988) | Sanofi | 2025-02-28 |
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (NCT06824181) | Sanofi | 2025-02-27 |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (NCT06824194) | Sanofi | 2025-02-18 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (NCT06834347) | Sanofi | 2025-02-12 |
| Description of Patients With Type 1 Diabetes Treated With Teplizumab (NCT06892002) | Sanofi | 2025-02-11 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (NCT06834360) | Sanofi | 2025-02-06 |
| French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) (NCT06837454) | Sanofi | 2025-02-04 |
| A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis (NCT06790121) | Sanofi | 2025-01-30 |
| Actual Use Trial of Tadalafil 5 mg (NCT06805513) | Sanofi | 2025-01-30 |
| Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP) (NCT06665308) | Sanofi | 2025-01-13 |
| A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (NCT06716424) | Sanofi | 2025-01-06 |
| Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data (NCT07094373) | Sanofi | 2025-01-01 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (NCT06500702) | Sanofi | 2024-12-19 |
| A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (NCT06691113) | Sanofi | 2024-12-16 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. (NCT06637631) | Sanofi | 2024-12-10 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs (NCT06671587) | Sanofi | 2024-12-10 |
| A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies (NCT06616415) | Sanofi | 2024-12-04 |
| A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany (NCT06695897) | Sanofi | 2024-12-02 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) (NCT06687967) | Sanofi | 2024-11-28 |
| Goal Attainment and Physical Activity in People With Hemophilia A (NCT06530030) | Sanofi | 2024-11-26 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) (NCT06687980) | Sanofi | 2024-11-25 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration (NCT06660667) | Sanofi | 2024-11-21 |